Ovarian Cancer - Healing Genes

Ovarian Cancer

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer

Phase 2


Doctors at the National Institutes of Health are recruiting participants for a large study on how well a gene-modified immunotherapy can shrink tumors of these cancers:

  • Glioblastoma
  • Non-Small Cell Lung Cancer
  • Ovarian Cancer
  • Breast Cancer
  • Gastrointestinal/Genitourinary Cancer

The investigational therapy will withdraw white blood cells from the patient and, utilizing gene editing, the white blood cells will be taught to target their tumors. After a 1-week course of chemotherapy, the altered white blood cells will be returned by IV and their growth encouraged with additional therapy. Recovery for 1 to 2 weeks in the hospital is expected, then participants will be followed for ~2 years.


  • Be 18 to 70 years of age
  • Not be pregnant or breastfeeding
  • Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment
  • Meet several screening requirements regarding the status of their cancer and overall health, past treatments, and their current medications


  1. Prescreening tests to confirm eligibility of the patient to participate, including 1 to 2 weeks of repeated lab screenings
  2. White blood cells will be drawn via IV and a central line, or IV catheter, will be placed in the patient’s chest
  3. Over several weeks, the patient will receive no treatment while the cells are gene-modified in a lab
  4. One week stay in hospital for a course of chemotherapy to reduce the patient’s existing bone marrow
  5. The patient’s changed cells will be re-administered along with a drug over 1 to 5 days to encourage their growth
  6. After hospital discharge, an antibiotic and possibly an antiviral will be taken for at least 6 months while screening tests will be required every few months for year 1 post treatment, then each 6 months for year 2, then as determined.


The study site is at the National Institutes of Health Clinical Center in Bethesda, Maryland. Map.

Primary contact: Ellen Bodurian | [email protected] | (866) 820-4505

NIH Clinical Center contact NCI/Surgery Branch Recruitment Center | [email protected] | 866-820-4505



The National Cancer Institute (NCI)

Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader